Methylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis

Oncology Letters

Volumn 8, Issue 1, 2014, Pages 397-403

  Fujita, Noriko ^a   Kagara, Naofumi ^a   Yamamoto, Noriaki ^b   Shimazu, Kenzo ^a   Shimomura, Atsushi ^a   Shimoda, Masafumi ^a   Maruyama, Naomi ^a   Naoi, Yasuto ^a   Morimoto, Koji ^a   Oda, Naofumi ^a   Kim, Seung Jin ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SYSMEX CORPORATION   (Japan)

Author keywords

Breast cancer; DNA; Methylation; Neoadjuvant chemotherapy; Prognosis; Serum

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GLUTATHIONE TRANSFERASE P1; GOSERELIN; PACLITAXEL; PROGESTERONE RECEPTOR; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; DNA CONTENT; DNA METHYLATION; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 84901193233     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2068     Document Type: Article

References (26)

1. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C and Duchateau L: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19: 4224-4237, 2001.
2. Singletary SE: Neoadjuvant chemotherapy in the treatment of stage II and III breast cancer. Am J Surg 182: 341-346, 2001.
3. Wolmark N, Wang J, Mamounas E, Bryant J and Fisher B: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr: 96-102, 2001.
4. Bear HD, Anderson S, Smith RE, et al: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24: 2019-2027, 2006.
5. Müller HM, Widschwendter A, Fiegl H, et al: DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 63: 7641-7645, 2003.
6. Göbel G, Auer D, Gaugg I, et al: Prognostic significance of methylated RASSF1A and PITX2 genes in blood-and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat 130: 109-117, 2011.
7. Sharma G, Mirza S, Parshad R, et al: Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci 87: 83-91, 2010.
8. Lo PK and Sukumar S: Epigenomics and breast cancer. Pharmacogenomics 9: 1879-1902, 2008.
9. Martens JW, Margossian AL, Schmitt M, Foekens J and Harbeck N: DNA methylation as a biomarker in breast cancer. Future Oncol 5: 1245-1256, 2009.
10. Yamamoto N, Nakayama T, Kajita M, et al: Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay. Breast Cancer Res Treat 132: 165-173, 2012.
11. Fujita N, Nakayama T, Yamamoto N, et al: Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients. Oncology 83: 273-282, 2012.
12. Sharma G, Mirza S, Parshad R, Gupta SD and Ralhan R: DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients. Tumour Biol 33: 1837-1843.
13. Avraham A, Uhlmann R, Shperber A, et al: Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients. Int J Cancer 131: E1166-E1172.
14. Goldhirsch A, Glick JH, Gelber RD, Coates AS and Senn HJ: Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19: 3817-3827, 2001.
15. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B and Senn HJ: Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21: 3357-3365, 2003.
16. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B and Senn HJ; Panel members: Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16: 1569-1583, 2005.
17. Arai T, Miyoshi Y, Kim SJ, et al: Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers. Eur J Surg Oncol 34: 734-738, 2008.
18. Robbins P, Pinder S, de Klerk N, et al: Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 26: 873-879, 1995.
19. Schwarzenbach H, Hoon DS and Pantel K: Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11: 426-437, 2011.
20. Fleischhacker M and Schmidt B: Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 1775: 181-232, 2007.
21. Kowalewska M, Nowak R and Chechlinska M: Implications of cancer-associated systemic inflammation for biomarker studies. Biochim Biophys Acta 1806: 163-171, 2010.
22. Matuschek C, Bölke E, Lammering G, et al: Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease. Eur J Med Res 15: 277-286, 2010.
23. Van der Auwera I, Elst HJ, Van Laere SJ, et al: The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer 100: 1277-1286, 2009.
24. Schwarzenbach H, Alix-Panabières C, Müller I, et al: Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 15: 1032-1038, 2009.
25. Mathiesen RR, Borgen E, Renolen A, et al: Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Res 14: R117.
26. Xenidis N, Ignatiadis M, Apostolaki S, et al: Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 27: 2177-2184, 2009.